Pharmacological approaches to potentiate glucose-stimulated insulin secretion (GSIS), such as analogues of the incretin glucagon-like pepide-1 (GLP-1), have been successfully exploited over many years to treat type 2 diabetes (T2D) [1]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.